CD19 and B-cell non-Hodgkin lymphoma: In turn, all B-cell lymphoma cases (5/5) could be easily distinguished from pediatric solid tumors with screening panel 1 (Table S2) by the expression of B-cell markers (CD19+, cyCD79a+, CD22+) in association with CD45+lo or CD45+, while these markers were systematically absent in all 26 pediatric solid tumors.